quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·51d
PRRelease
Theravance Biopharma Inc. logo

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

TBPH· Theravance Biopharma Inc.
Health Care
Original source

Companies

  • TBPH
    Theravance Biopharma Inc.
    Health Care

Recent analyst ratings

  • Mar 5UpdateOppenheimer-
  • Mar 4UpdateB. Riley Securities$14.00
  • Dec 3UpdateOppenheimer$27.00
  • Sep 12UpdateB. Riley Securities$28.00
  • Aug 6UpdateLeerink Partners$10.00
  • Apr 12UpdateBTIG Research$21.00

Related

  • INSIDER20d
    SEC Form 4 filed by Winningham Rick E
  • INSIDER20d
    SEC Form 4 filed by Sawaf Aziz
  • INSIDER20d
    SEC Form 4 filed by Grimaud Brett A.
  • INSIDER20d
    SEC Form 4 filed by Farnum Rhonda
  • SEC24d
    Theravance Biopharma Inc. filed SEC Form 8-K: Other Events
  • SEC29d
    Amendment: SEC Form SCHEDULE 13D/A filed by Theravance Biopharma Inc.
  • SEC31d
    SEC Form 10-K filed by Theravance Biopharma Inc.
  • SEC35d
    Theravance Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022